Founded in 2013, Cambium Bio Limited (ASX: CMB) focuses on harnessing the regenerative potential of human platelet lysate and mesenchymal stem cells to develop cutting-edge biologic therapies. The company's lead product candidate, Elate Ocular®, is being developed to treat dry eye disease, a condition affecting millions worldwide. Additionally, Cambium Bio's stem cell platform, Progenza™, is targeted towards therapies for knee osteoarthritis and other tissue regeneration indications. Committed to advancing its pipeline through clinical development and commercialisation, Cambium Bio aims to provide transformative treatments that enhance patient outcomes.
Cambium Bio Limited (ASX:CMB)
Breakthrough medicines. By design.
About Us
Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue regeneration applications.
The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics with a primary focus on ophthalmology.
Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease.
In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue regeneration indications.
Cambium Bio is committed to advancing its pipeline through clinical development and commercialisation, with the goal of providing transformative treatments to improve patient outcomes.
Company Overview
Board & Management
Karolis Rosickas
Chief Executive Officer
- Co-founder of digital therapeutics company OME Health, London, UK.
- Co-founder of cell therapy CDMO SingCell, Singapore.
- Vice President, Healthcare Investment Banking, HSBC, London, UK.
- Finance Director, Danone Early Life & Clinical Nutrition, Baltic States.
- Regional Treasurer for Asia at the International Society for Cell and Gene Therapy (ISCT).
- MS in Biotechnology at Northeastern University, Boston, Massachusetts, USA.
- MBA at IESE Business School, Barcelona, Spain.
- Joined Cambium Bio in 2020.
Dr Edmund K. Waller
Executive Director
- Co-founder of Cambium Medical Technologies in 2013.
- Professor of Medicine, Pathology & Hematology/Oncology at Emory University, Atlanta, GA.
- Vice President, Healthcare Investment Banking, HSBC, London, UK.
- Multiple other roles at Emory University, Atlanta, GA.
- PhD at The Rockefeller University, New York City, NY.
- MD at Cornell University Medical College, Ithaca, NY.
- BA at Harvard University, Cambridge, MA.
Dr Sebastian Tseng
Non-Executive Director
- Founder and Chairman of Zheng Yang Biomedical Technology Co., Ltd. (ZYBT), a holding company for AventaCell, Dr. Wells, and other biomedical and healthcare businesses.
- Assistant Professor at Taipei Medical University.
- Chairman of the Asia Pacific Academy of Implant Surgery.
- Doctor of Dental Surgery at the College of Dentistry of New York University.
- Bachelor of Dental Surgery at College of Chung Shan Medical University.
Terence A. Walts
Executive Director
- Co-founder of Cambium Medical Technologies in 2013.
- CEO of 3Ti (automated blood analyzer start-up).
- CEO of Refocus Group (ophthalmic device start-up).
- CMO of Autonomous Technologies (refractive surgery start-up).
- VP WW Sales, Marketing and BD at Novartis (CIBA Vision).
- MBA at The University of Notre Dame, Indiana.
- BS in Marketing at Indiana University, Indiana.
Barry Sechos
Non-Executive Chairman
- 20+ years of experience as a director, business executive, and corporate lawyer.
- Executive Director of Sherman Group.
